Wegovy prescriptions with 'few checks': what's actually required?

What did @thetimes actually say?

The Times journalist ran a sting operation: she described herself as a healthy weight, added roughly three stone to her reported weight on online consultation forms, and received Wegovy prescriptions from both Boots and Superdrug Online Doctor within 24 hours, each for under £200. Her core argument is that these platforms have no way to verify self-reported weight, and that this gap is already sending young women to A&E with serious complications.

She also repeated warnings from doctors that patients, including some with eating disorders, are lying about their BMI to access semaglutide. Her proposed fix, echoing NHS leaders, is mandatory in-person weight verification before any online prescription is issued.

Does the science back this up?

The safety concerns are real and well-documented. The gap in verification she exposed is genuine. But the framing around how dangerous Wegovy is for healthy-weight people deserves more nuance than the video provides.

Semaglutide's approval thresholds exist for good reason. The pivotal STEP trials (Wilding et al., 2021, New England Journal of Medicine) enrolled patients with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. There is no large-scale efficacy or safety data for people at a healthy BMI using semaglutide for weight loss, which is a meaningful gap.

The pancreatitis risk she mentions is real but context matters. A 2023 study in JAMA Internal Medicine (Wang et al.) found a statistically significant association between GLP-1 receptor agonists and acute pancreatitis, though absolute risk remained low. Nausea and dehydration are common, reported in roughly 40-44% of STEP trial participants at therapeutic doses. Neither trivial nor catastrophic in otherwise healthy adults, but meaningfully riskier if someone has an undetected eating disorder or low body weight.

What did they get wrong (or right)?

She got the core story right. The verification problem is real, and the BMI threshold is clinically meaningful, not just a technicality.

Where the video oversimplifies: "deadly complications" is a stretch for the average healthy-weight person who obtains semaglutide. Pancreatitis is serious, but the video presents it as a likely outcome rather than a documented but uncommon risk. The phrase "stream of patients" coming into A&E is anecdotal and not supported by published incidence data cited in the video. No study is referenced. That matters when you are building a regulatory argument.

She also conflates Wegovy and Ozempic in a way that is mostly accurate but could mislead. Both contain semaglutide, but Wegovy is approved at higher doses specifically for weight management, while Ozempic is approved for type 2 diabetes at lower doses. They are not interchangeable products, even though the active molecule is the same. Her description of them as essentially the same drug is a simplification that could cause confusion among viewers self-researching options.

What should you actually know?

If you are considering any GLP-1 medication through an online platform, the verification question she raises is the right one to ask. A legitimate telehealth provider should require documented weight and height, review of relevant medical history, and screening for contraindications including a history of eating disorders, thyroid cancer, or pancreatitis. Any platform that skips those steps is not practicing safe prescribing, full stop.

The MHRA in the UK has issued guidance on semaglutide prescribing, and NHS England has flagged supply pressures partly caused by demand from people who do not meet clinical criteria. If you do meet criteria, a properly supervised GLP-1 prescription can be appropriate and effective. The issue is not the drug class. The issue is prescribing without adequate clinical information, which is what this video documented happening in practice.

• Wegovy requires a BMI of 30 or above (or 27 with comorbidities) for clinical approval.
• Self-reported weight on online forms is currently unverifiable at scale by most UK online pharmacies.
• People with active or historical eating disorders face elevated risk from GLP-1 medications and require specialist screening.
• Pancreatitis is a documented but low-absolute-risk complication, not a likely outcome for most users.